Soluble immune markers in the different phases of chronic hepatitis B virus infection

Abstract Chronic hepatitis B virus (HBV) infection may follow four different consecutive phases, which are defined by virology as well as biochemical markers and differ in terms of prognosis and need for antiviral treatment. Currently, host responses reflected by immune markers are not considered in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Steffen B. Wiegand, Bastian Beggel, Anika Wranke, Elmira Aliabadi, Jerzy Jaroszewicz, Cheng-Jian Xu, Yang Li, Michael P. Manns, Thomas Lengauer, Heiner Wedemeyer, Anke R. M. Kraft, Christine S. Falk, Markus Cornberg
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2019
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f7ac612f63a345c6b2c5dd3549909b29
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f7ac612f63a345c6b2c5dd3549909b29
record_format	dspace
spelling	oai:doaj.org-article:f7ac612f63a345c6b2c5dd3549909b292021-12-02T15:09:57ZSoluble immune markers in the different phases of chronic hepatitis B virus infection10.1038/s41598-019-50729-52045-2322https://doaj.org/article/f7ac612f63a345c6b2c5dd3549909b292019-10-01T00:00:00Zhttps://doi.org/10.1038/s41598-019-50729-5https://doaj.org/toc/2045-2322Abstract Chronic hepatitis B virus (HBV) infection may follow four different consecutive phases, which are defined by virology as well as biochemical markers and differ in terms of prognosis and need for antiviral treatment. Currently, host responses reflected by immune markers are not considered in this definition. We aimed to study soluble immune markers and their distribution in different phases of chronic HBV infection. In this cross-sectional retrospective study, we investigated a panel of 14 soluble immune markers (SIM) including CXCL10 in 333 patients with chronic HBV infection. In a small cohort of HBeAg positive patients we analyzed SIM before and after HBeAg seroconversion and compared seroconverters to patients with unknown outcome. Significant differences were documented in the levels of several SIM between the four phases of chronic HBV infection. The most pronounced difference among all investigated SIM was observed for CXCL10 concentrations with highest levels in patients with hepatitis. TGF-β and IL-17 revealed different levels between HBeAg negative patients. HBeAg positive patients with HBeAg seroconversion presented higher amounts of IL-12 before seroconversion compared to HBeAg positive patients with unknown follow up. SIM such as CXCL10 but also IL-12, TGF-β and IL-17 may be useful markers to further characterize the phase of chronic HBV infection.Steffen B. WiegandBastian BeggelAnika WrankeElmira AliabadiJerzy JaroszewiczCheng-Jian XuYang LiMichael P. MannsThomas LengauerHeiner WedemeyerAnke R. M. KraftChristine S. FalkMarkus CornbergNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 9, Iss 1, Pp 1-10 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Steffen B. Wiegand Bastian Beggel Anika Wranke Elmira Aliabadi Jerzy Jaroszewicz Cheng-Jian Xu Yang Li Michael P. Manns Thomas Lengauer Heiner Wedemeyer Anke R. M. Kraft Christine S. Falk Markus Cornberg Soluble immune markers in the different phases of chronic hepatitis B virus infection
description	Abstract Chronic hepatitis B virus (HBV) infection may follow four different consecutive phases, which are defined by virology as well as biochemical markers and differ in terms of prognosis and need for antiviral treatment. Currently, host responses reflected by immune markers are not considered in this definition. We aimed to study soluble immune markers and their distribution in different phases of chronic HBV infection. In this cross-sectional retrospective study, we investigated a panel of 14 soluble immune markers (SIM) including CXCL10 in 333 patients with chronic HBV infection. In a small cohort of HBeAg positive patients we analyzed SIM before and after HBeAg seroconversion and compared seroconverters to patients with unknown outcome. Significant differences were documented in the levels of several SIM between the four phases of chronic HBV infection. The most pronounced difference among all investigated SIM was observed for CXCL10 concentrations with highest levels in patients with hepatitis. TGF-β and IL-17 revealed different levels between HBeAg negative patients. HBeAg positive patients with HBeAg seroconversion presented higher amounts of IL-12 before seroconversion compared to HBeAg positive patients with unknown follow up. SIM such as CXCL10 but also IL-12, TGF-β and IL-17 may be useful markers to further characterize the phase of chronic HBV infection.
format	article
author	Steffen B. Wiegand Bastian Beggel Anika Wranke Elmira Aliabadi Jerzy Jaroszewicz Cheng-Jian Xu Yang Li Michael P. Manns Thomas Lengauer Heiner Wedemeyer Anke R. M. Kraft Christine S. Falk Markus Cornberg
author_facet	Steffen B. Wiegand Bastian Beggel Anika Wranke Elmira Aliabadi Jerzy Jaroszewicz Cheng-Jian Xu Yang Li Michael P. Manns Thomas Lengauer Heiner Wedemeyer Anke R. M. Kraft Christine S. Falk Markus Cornberg
author_sort	Steffen B. Wiegand
title	Soluble immune markers in the different phases of chronic hepatitis B virus infection
title_short	Soluble immune markers in the different phases of chronic hepatitis B virus infection
title_full	Soluble immune markers in the different phases of chronic hepatitis B virus infection
title_fullStr	Soluble immune markers in the different phases of chronic hepatitis B virus infection
title_full_unstemmed	Soluble immune markers in the different phases of chronic hepatitis B virus infection
title_sort	soluble immune markers in the different phases of chronic hepatitis b virus infection
publisher	Nature Portfolio
publishDate	2019
url	https://doaj.org/article/f7ac612f63a345c6b2c5dd3549909b29
work_keys_str_mv	AT steffenbwiegand solubleimmunemarkersinthedifferentphasesofchronichepatitisbvirusinfection AT bastianbeggel solubleimmunemarkersinthedifferentphasesofchronichepatitisbvirusinfection AT anikawranke solubleimmunemarkersinthedifferentphasesofchronichepatitisbvirusinfection AT elmiraaliabadi solubleimmunemarkersinthedifferentphasesofchronichepatitisbvirusinfection AT jerzyjaroszewicz solubleimmunemarkersinthedifferentphasesofchronichepatitisbvirusinfection AT chengjianxu solubleimmunemarkersinthedifferentphasesofchronichepatitisbvirusinfection AT yangli solubleimmunemarkersinthedifferentphasesofchronichepatitisbvirusinfection AT michaelpmanns solubleimmunemarkersinthedifferentphasesofchronichepatitisbvirusinfection AT thomaslengauer solubleimmunemarkersinthedifferentphasesofchronichepatitisbvirusinfection AT heinerwedemeyer solubleimmunemarkersinthedifferentphasesofchronichepatitisbvirusinfection AT ankermkraft solubleimmunemarkersinthedifferentphasesofchronichepatitisbvirusinfection AT christinesfalk solubleimmunemarkersinthedifferentphasesofchronichepatitisbvirusinfection AT markuscornberg solubleimmunemarkersinthedifferentphasesofchronichepatitisbvirusinfection
_version_	1718387791907258368

Soluble immune markers in the different phases of chronic hepatitis B virus infection

Ejemplares similares